ACADIA PHARMACEUTICALS INC — Form 8-K
Filed August 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
ACADIA reported Q2 2026 total revenues of $308M (up 16% YoY), with DAYBUE sales of $125M (+30% YoY) and NUPLAZID sales of $183M (+9% YoY). The company raised full-year 2026 total revenue guidance to $1.24–$1.30B (from $1.22–$1.28B) and DAYBUE guidance to $480–$510M (from $460–$490M), while reaffirming NUPLAZID guidance at $760–$790M. Phase 2 remlifanserin results for Alzheimer's disease psychosis are expected September–October 2026; the company also received FDA Fast Track designation and EMA positive opinion for DAYBU in Europe.
Why this rating
Guidance raise, strong organic revenue growth, and pipeline catalyst (Phase 2 readout) are meaningful for ~$2.3B company; material but not transformational absent Phase 2 data.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.